Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-phase treatment before R-CHOP in elderly patients with newly diagnosed DLBCL
KCT0003916Phase 2Recruiting
- Sponsor
- Dong-A Pharmaceutical
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide + doxorubicin + vincristine + prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Dong-A Pharmaceutical. Started Jan 2017; status: recruiting.
02
Drugs
cyclophosphamide + doxorubicin + vincristine + prednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0003916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003916.